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BC - blood culture, Bcc - Burkholderia cepacia complex, CF - cystic fibrosis, CGD - 
chronic granulomatous disease, CVL - central venous line, EBV - Epstein-Barr virus, HLH 
- hemophagocytic lymphohistiocytosis, MLST - multi-locus sequence type, PTLD - post-









‘Cepacia syndrome’ caused by Burkholderia cepacia complex and often found to be 
associated in patients with cystic fibrosis, carries a high mortality rate. It is rare for 
Burkholderia multivorans, a species within the Burkhoderia cepacia complex to cause 
‘cepacia syndrome’ even among the cystic fibrosis patients.  This is the first reported 
fatal case of ‘cepacia syndrome’ caused by Burkholderia multivorans occurring in a non-
cystic fibrosis pediatric liver transplant recipient. We describe the unique 
characteristics of this pathogen among the non-cystic fibrosis population and the 
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The Burkholderia cepacia complex (Bcc), consisting of 22 species, is a group of aerobic, 
Gram-negative, non-spore-forming bacilli that are phenotypically similar but 
genotypically distinct(1). Bcc are well recognized opportunistic pathogens associated 
with high morbidity and mortality in persons with cystic fibrosis (CF)(2). Bcc infections 
in non-CF settings have been described in nosocomial outbreaks attributable to 
contaminated disinfectants, intravenous solutions, and medical devices, and in 
opportunistic infections in immunocompromised hosts such as patients with chronic 
granulomatous disease (CGD) or malignancies(2-4).  ‘Cepacia syndrome’, a necrotizing 
pneumonia characterized by rapid clinical deterioration and septicemia frequently 
leading to death(5), has mostly been associated with Burkholderia cenocepacia, a Bcc 
species, isolated most commonly in CF patients(2). Cases of cepacia syndrome 
secondary to Burkholderia multivorans have been described infrequently(6-8), but no 
cases have been reported in the literature outside of the CF population.  
 
We present the first report of a case of cepacia syndrome caused by B. multivorans in a 




A 23-month old Caucasian male, post-liver transplant was transferred from a tertiary 
children’s hospital to our transplant center with persistent fever of unknown cause. His 
past medical history included biliary atresia and Kasai surgery at 58 days of age. He had 
normal newborn screening and sweat test. His clinical course was complicated by 
ascending cholangitis, worsening jaundice and recurrent ascites with progression to 
end-stage liver disease requiring a living-related liver transplant from his father at 6 
months of age. Donor and recipient were both positive for Epstein-Barr virus (EBV) IgG, 
while both donor and recipient serostatus for cytomegalovirus was negative. He was 
placed on standard immunosuppression with steroid and tacrolimus post-transplant. 
He was weaned off steroids three months post-transplant. At 12 months of age, he 
developed intestinal polymorphous post-transplant lymphoproliferative disorder 
(PTLD). Serum EBV quantitative PCR became undetectable after four doses of 
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remained well apart from a single episode of perianal abscess, treated with a 3-week 
course of amoxicillin/clavulanic acid.  
 
The current illness began with fever presenting to his local community hospital. He was 
subsequently transferred to his local academic hospital for ongoing recurrent fever 
after receiving 4 days of cefotaxime. At the local academic hospital, he was empirically 
treated with intravenous piperacillin/tazobactam and tobramycin before his blood 
culture (BC) became positive for Bcc, at which time his therapy was switched to 
ceftazidime and ciprofloxacin, to which the Bcc isolate was susceptible (See Figure 2). A 
central venous line (CVL) was inserted due to difficult intravenous access after the BC 
became negative, and his antibiotics were continued for another 2 weeks. Other 
investigations, including cerebrospinal fluid and urine culture, chest x-ray, head CT 
scan, and an abdominal ultrasound were all unremarkable. He had a single recurrence 
of fever, which was attributable to a possible viral infection on the last day of 
antimicrobial therapy and he was given piperacillin/tazobactam and tobramycin for an 
additional 48 hours until repeat BC was negative. His CVL was removed prior to 
discharge.  Given repeatedly negative BCs and a recent serum EBV viral load of 
5.6x103 
 
copies per mL, PTLD was suspected as a potential etiology of the recurrent fever 
within 5 days of discharge. Tacrolimus levels were measured between 2-3ug/L before 
discontinuation. Endoscopic assessment with luminal biopsies, however, showed no 
evidence of EBV encoded RNA by in situ hybridization. Another CVL was inserted. A 
chest x-ray taken at his initial hospital admission was reported as unremarkable. 
However, a repeat chest x-ray prior to transfer showed small patchy opacities in both 
lungs fields.  
At our institution, he remained febrile. Physical examination was unremarkable except 
for mildly enlarged tonsils.  There was no lymphadenopathy or palpable abdominal 
masses, and his chest was clear. Within 24 hours, however, he quickly deteriorated, 
developing septic shock and required oxygen supplementation. Meropenem and 
vancomycin were commenced to broaden coverage in the context of an 
immunocompromised patient who failed empiric therapy with pipercillin/tazobactam, 
ceftazidime and ciprofloxacin. Repeat chest x-ray showed worsening diffuse, ill-defined 
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infection (Figure 1A) and amphotericin B was added.  The CVL was removed after both 
peripheral and CVL BCs simultaneously became positive for Bcc, which was later 
identified to be B. multivorans. Despite broadening antimicrobials to include 
ciprofloxacin and sulfamethoxazole/trimethoprim, his condition worsened and he died 
from disseminated intravascular coagulation, multi-organ failure and secondary 
hemophagocytic lymphohistiocytosis (HLH).  
 
Postmortem examination revealed necrotic abscesses in both lungs (Figure 1B-1D) and 
most organs, including liver, lymph nodes, bone marrow, brain, spleen, kidneys and 
adrenal glands. Lung tissue culture grew B. multivorans.  Hemophagocytosis was seen 
in the liver confirming the clinical suspicion of secondary HLH. A large, recent 
intracerebral hemorrhage of the left cerebral hemisphere was also observed, which was 
negative for bacteria and fungal elements on Gram and Gormori methenamine silver 
stain. There was no pathological evidence to suggest the presence of PTLD, liver 
allograft rejection, CGD, or CF.  
 
Further molecular typing of the B. multivorans isolate revealed that it was most closely 
related to a multi-locus sequence type (MLST)(9), ST355, which had only been 
previously identified from the blood culture of a patient with CGD in the United 
States(10). Our patient’s isolate differed by random amplified polymorphic DNA 
analysis(11) and was just one base pair different in one of the 7 MLST alleles tested 
compared to the isolate from the CGD patient.  Repetitive extragenic palindromic PCR 
using BOX A1R primer(12), however, found these two isolates to be identical.  
 
To our knowledge, this is the first report of B. multivorans infection presenting as 
‘cepacia syndrome’ in a non-CF liver transplant patient. Increased awareness of the 
severity of this condition amongst transplant physicians may lead to more rapid 
diagnosis with close monitoring and frequent follow-up, and longer duration of 
antibiotic therapy.  
 
We performed a literature review of cases of Bcc infections in non-CF and non-outbreak 
settings by searching the Medline database since 1996 using the terms “Burkholderia” 
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reports(3, 13-19) and one was a prospective observational study(4). Species 
identification was only available for 3 patients; two involved B. cenocepacia and one 
with B. multivorans(16, 19). Four cases (Patient 2, 3, 8 and 12 in Table 1) fit the clinical 
presentation of ‘cepacia syndrome’ as characterized by rapid respiratory decline with 
bacteremia and necrotizing pneumonia.  Two of these patients had underlying CGD.  All 
were fatal except one (Patient 8).  
 
The incidence of B.  multivorans infection has been increasing in CF patients, but it is a 
rarely seen infection in the non-CF population(10). In one New Zealand study, B. 
multivorans accounted for 79.5% of Bcc infections in CF patients, but only 28% in the 
non-CF group(20). Burkholderia lata and Burkholderia stabilis, with low level of 
diversity based on MLST, accounted for 44% of the non-CF Bcc infections in the 
study(20). In contrast to B. cenocepacia where patient-to-patient transmission has been 
well described in CF in the past, initial B. multivorans infection in CF patients is thought 
to be acquired from the environment(21).  Among the non-CF group, it is thought that 
person-to-person spread is unlikely, as the infected patients were separated temporally 
and geographically with no epidemiological links(10, 20). Infection control precautions 
should be no different for immunosuppressed patients.  
 
In our case, although the patient had a liver transplantation that may have contributed 
to the development of this infection, he was only on minimal immunosuppression at the 
time of infection. His rapid clinical deterioration is uncharacteristic for B. multivorans 
infections in a non-CF setting. The underlying reason for the severity of his illness and 
source of infection remain unclear. The incidence of Bcc infection in transplant patients 
is unknown. Recognition of chest x-ray changes (Figure 1A), in the setting of recent Bcc 
bacteremia, should alert transplant physicians to possible cepacia syndrome.  Despite 
the recognition of the clinical significance of Bcc infections in both 
immunocompromised and CF patients, there is a lack of evidenced based antibiotic 
treatment for this infection(22, 23). Because of the potential for emergence of 
resistance while on monotherapy and data from synergy studies, some would consider 
treatment with multiple intravenous antibiotics initially, follow by two to three drug 
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therapy is not clear, the possibility of cepacia syndrome may suggest the need for a 
longer duration of antibiotics with close monitoring. 
 
This is the first case report of B. multivorans presenting as ‘cepacia syndrome’ in a non-
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Figure 1: Imaging, autopsy and histology findings of ‘cepacia syndrome’.  
A. Chest x-ray showed diffusely ill-defined density nodules in bilateral lungs and 
small right pleural effusion.  
B. Autopsy revealed diffuse multiple foci of necrotic abscesses (red arrow) within 
both lungs.  
C. Image shows histiocytes at the periphery and karyorrhectic debris toward the 
center of the abscess.  
D. Immunohistochemical staining for CD68 (Dako, Carpinteria,CA) confirming 
marked numbers of histiocytes at the periphery of the lung abscess. 
Figure 2: Clinical events with key investigation findings and treatment course (including 
Bcc susceptibility results).  
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TABLE:  
















Decline  Sepsis Outcome 
                    
Lacy et al. 1 3.5, M CGD unknown Y unclear (pleural 
effusion) 
Y Y died 
 2 0.6, M CGD unknown Y Y Y Y died 





unknown Y Y Y Y died 




unknown N Y Y unclear died 
 5 43, F Lupus-like syndrome; 
migraines; 
hypothyroidism 
unknown N Y Y unclear died 
Sirinavain et al. 6 1.4, M CGD unknown N Y Y Y recovered 
Whitehouse et 
al. 




N Y N N recovered 
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Satpute et al. 9 2, M healthy  B. 
cenocepaci
a 
Y N N Y recovered 
 10 9, M immunocompromised B. 
cenocepaci
a 
Y N N Y recovered 
Suresh et al. 11 63, M healthy unknown N Y N unclear recovered 
Hauser et al. 12 64, M HT, Type 2-DM unknown Y Y Y Y died 
Martino et al. 13 * malignancies unknown Y Y unknown Y died 
 14 * malignancies unknown Y Y unknown Y recovered 
 15 * malignancies unknown Y N unknown N recovered 
 16 * malignancies unknown Y N unknown N recovered 
 17 * malignancies unknown Y N unknown N recovered 
                    
* Prospective trial, specific age and sex of patients not available 
















Figure 1: Imaging, autopsy and histology findings of ‘cepacia syndrome’. (A) Chest x-ray 
showed diffusely ill-defined density nodules in bilateral lungs and small right pleural 
effusion. (B) Autopsy revealed diffuse multiple foci of necrotic abscesses (red arrow) 
within both lungs. (C-D) Photomicrographs of lung abscess. (C) Image shows histiocytes 
at the periphery and karyorrhectic debris toward the center of the abscess. [H&E, 
original magnification x 100] (D) Immunohistochemical staining for CD68 (Dako, 
Carpinteria,CA) confirming marked numbers of histiocytes at the periphery of the lung 







Figure 2: Clinical events with key investigation findings and treatment course (including 
Bcc susceptibility results). 
 
PTLD, Post-transplant Lymphoproliferative Disorder; S, Sensitive; R, Resistant; BC, 
Blood Culture; CVL, Central Venous Line; Bcc, Burkholderia cepacia complex; CXR, Chest 
X-ray. 
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